Sezgin Bayindir Zerrin, Sova Matej, Yuksel Nilufer, Saso Luciano
Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara University 06560 Ankara Turkey.
Faculty of Pharmacy, University of Ljubljana SI-1000 Ljubljana Slovenia.
RSC Med Chem. 2025 Aug 22. doi: 10.1039/d5md00571j.
The NRF2/KEAP1 signaling pathway regulates the gene expression of numerous cytoprotective and detoxifying enzymes and is therefore essential for maintaining cellular redox homeostasis. Despite the increasing knowledge of NRF2 signaling complexity, dimethyl fumarate remains the sole NRF2-targeting therapy in clinical practice, used for multiple sclerosis. Ongoing research exploring the role of NRF2 in cancer, neurodegeneration, diabetes, and cardiovascular, renal, and liver diseases holds significant promise for future therapeutic innovation. The therapeutic potential of NRF2 modulators, while supported by positive research and clinical data, is often restricted due to factors including low solubility, poor stability, poor pharmacokinetic parameters, and a lack of specificity that results in off-target effects. Therefore, designing an effective pharmaceutical formulation is one of the significant barriers to their clinical translation. This article addresses these challenges by reviewing various drug delivery strategies with a particular emphasis on polymeric nanoparticles, liposomes, polymeric micelles, carbon nanotubes, micro/nano-emulsions, and biomimetic nanoparticles. The potential of these systems to enhance the pharmacological activities of NRF2 modulators-driven by their small particle size and customizable properties-is discussed on a disease-by-disease basis, focusing on cancer, neurodegenerative, and inflammatory diseases. While these systems have shown considerable success in preclinical studies, their clinical application is constrained by hurdles in safety, scalability, stability and regulatory compliance. This transition has not yet been achieved for NRF2 modulators, but intensive research is ongoing. Therefore, the overall aim of this article is to provide a comprehensive understanding of delivery strategies for NRF2 modulators, ultimately guiding the development of more effective therapies and improving their clinical applications.
NRF2/KEAP1信号通路调节众多细胞保护和解毒酶的基因表达,因此对于维持细胞氧化还原稳态至关重要。尽管对NRF2信号复杂性的认识不断增加,但富马酸二甲酯仍是临床实践中唯一用于治疗多发性硬化症的靶向NRF2的疗法。正在进行的探索NRF2在癌症、神经退行性疾病、糖尿病以及心血管、肾脏和肝脏疾病中的作用的研究,为未来的治疗创新带来了巨大希望。NRF2调节剂的治疗潜力虽有积极的研究和临床数据支持,但往往因低溶解度、稳定性差、药代动力学参数不佳以及缺乏特异性导致脱靶效应等因素而受到限制。因此,设计有效的药物制剂是其临床转化的重大障碍之一。本文通过综述各种药物递送策略来应对这些挑战,特别强调聚合物纳米颗粒、脂质体、聚合物胶束、碳纳米管、微/纳米乳液和仿生纳米颗粒。基于疾病逐一讨论了这些系统因其小粒径和可定制特性而增强NRF2调节剂药理活性的潜力,重点关注癌症、神经退行性疾病和炎症性疾病。虽然这些系统在临床前研究中已取得相当大的成功,但其临床应用受到安全性、可扩展性、稳定性和法规合规性等障碍的限制。NRF2调节剂尚未实现这种转变,但相关深入研究正在进行。因此,本文的总体目标是全面了解NRF2调节剂的递送策略,最终指导开发更有效的疗法并改善其临床应用。